Processa Pharmaceuticals (PCSA) Price to Sales (2014 - 2016)

Processa Pharmaceuticals (PCSA) has reported Price to Sales for 3 consecutive years, with 354.37 the latest figure, recorded in Q1 2016.

• For the quarter ending Q1 2016, Price to Sales fell 26.44% year-over-year to 354.37; the trailing twelve-month figure through Dec 2016 stood at 551.25 (up 1560.93% YoY), and the FY2016 full-year result was 551.25, up 1311.54% from the prior year.
• Price to Sales rose to 354.37 in Q1 2016 per PCSA's latest filing, from 253.12 in the prior quarter.
• Across five years, Price to Sales topped out at 1354.99 in Q4 2014 and bottomed at 115.62 in Q3 2015.
• Historically, Price to Sales has averaged 504.5 across 3 years, with a median of 354.37 in 2016.
• The widest YoY moves for Price to Sales: up 181.11% in 2015, down 81.32% in 2015.
• Over 3 years, Price to Sales stood at 1354.99 in 2014, then slumped by 81.32% to 253.12 in 2015, then soared by 40.0% to 354.37 in 2016.
• According to Business Quant data, Price to Sales over the past three periods registered 354.37, 253.12, and 115.62 for Q1 2016, Q4 2015, and Q3 2015 respectively.